CHARGE syndrome is an autosomal dominant malformation disorder caused by heterozygous loss of function mutations in the chromatin remodeler CHD7. Chd7 regulates the expression of Sema3a, which also contributes to the pathogenesis of Kallmann syndrome, a heterogeneous condition with the typical features hypogonadotropic hypogonadism and an impaired sense of smell. Both features are common in CHARGE syndrome suggesting that SEMA3A may provide a genetic link between these syndromes. Indeed, we find evidence that SEMA3A plays a role in the pathogenesis of CHARGE syndrome. First, Chd7 is enriched at the Sema3a promotor in neural crest cells and loss of function of Chd7 inhibits Sema3a expression. Second, using a Xenopus CHARGE model, we show that human SEMA3A rescues Chd7 loss of function. Third, to elucidate if SEMA3A mutations in addition to CHD7 mutations also contribute to the severity of the CHARGE phenotype, we screened 31 CHD7-positive patients and identified one patient with a heterozygous non-synonymous SEMA3A variant, c.2002A>G (p.I668V). By analyzing protein expression and processing, we did not observe any differences of the p.I668V variant compared with wild-type SEMA3A, while a pathogenic SEMA3A variant p.R66W recently described in a patient with Kallmann syndrome did affect protein secretion. Furthermore, the p.I668V variant, but not the pathogenic p.R66W variant, rescues Chd7 loss of function in Xenopus, indicating that the p.I668V variant is likely benign. Thus, SEMA3A is part of an epigenetic loop that plays a role in the pathogenesis of CHARGE syndrome, however, it seems not to act as a common direct modifier. † These authors contributed equally to this work. # These authors are co-last authors.
Introduction
Semaphorins are transmembrane or secreted proteins, which were originally identified as guidance factors controlling axonal pathfinding during the development of the nervous system (1) . The large family of semaphorins was classified into eight groups according to structural similarities (2) . Semaphorin-3A (MIM 603961) belongs to Subgroup 3, a group of secreted proteins playing a role in neural crest cell and axon guidance. A function of Sema3a as guidance factor controlling morphogenetic processes, like the migration of neural crest cells, is well established (3) (4) (5) (6) . Recently, it was demonstrated that SEMA3A mutations contribute to the phenotype of Kallmann syndrome (HH16; MIM 614897), a genetically heterogeneous congenital disorder, characterized by a combination of hypogonadotropic hypogonadism and impaired sense of smell (7) (8) (9) . These two features are owing to migration defects of GnRH producing cells and olfactory neurons on their way from the olfactory placode to the hypothalamus and bulbus olfactorius (10, 11) . Therefore, it is not surprising that many of the genes linked to Kallmann syndrome have a function in axon growth and guidance. Indeed, several SEMA3A mutations have been detected in patients with Kallmann syndrome (8, 9) . A disease modifying effect of the SEMA3A mutations or a digenic/oligenic inheritance was postulated because SEMA3A mutations alone seem not to be sufficient to produce the Kallmann syndrome phenotype (9) .
Hypogonadotropic hypogonadism and an impaired sense of smell are two features, which are also frequently observed in CHARGE syndrome (12) (13) (14) (15) , a congenital malformation disorder affecting several organ systems. CHARGE syndrome is caused by heterozygous loss of function mutations in CHD7 (MIM 608892), a chromodomain helicase DNA-binding protein required for ATP-dependent chromatin remodeling. Besides causing CHARGE syndrome, heterozygous CHD7 mutations (HH5; MIM 612370) have also been identified in a minority of Kallmann syndrome patients, which exhibit features reminiscent of a mild CHARGE phenotype, like for example hearing loss. Therefore, it has been suggested that Kallmann syndrome, caused by CHD7 mutations, and CHARGE syndrome are allelic disorders, whereby Kallmann syndrome represents the mild end of the phenotypic spectrum (16) . Consistent with this hypothesis, we could recently demonstrate a regulatory loop between Chd7 and Sema3a using a Chd7-deficient mouse model (Chd7 Whi/Whi ) and by performing knockdown experiments in Xenopus laevis. In both model systems a downregulation of Chd7 led to a reduction in the Sema3a expression (17) . Further support for an epigenetic regulation of Class 3 semaphorins by Chd7 comes from a genome-wide transcriptional analysis of mice with a conditional ablation of Chd7 in early cardiogenic mesoderm (18) . Interestingly, bi-allelic loss of function mutations in SEMA3A were recently discovered to cause a syndrome with short stature, skeletal anomalies, congenital heart defects, a micropenis, and variable additional anomalies (19, 20) . Although this syndrome differs from CHARGE syndrome, an overlap of the affected tissues could be observed. Taken together these data support a role of SEMA3A in the pathogenesis of CHARGE syndrome. However, so far pathogenic SEMA3A variants have not been identified as the causes of CHARGE syndrome in patients lacking a pathogenic CHD7 mutation. Therefore, the aim of this study was to investigate a possible epigenetic link between CHD7 and SEMA3A and the role of SEMA3A in the pathogenesis of CHARGE syndrome in a wider sense.
Results

In vivo evidence for an epigenetic control of Sema3a expression by Chd7
To analyze the role of SEMA3A in the pathogenesis of CHARGE syndrome, we used the Xenopus in vivo model system. Previously, it was shown that loss of function of Chd7 in Xenopus recapitulates all major features of CHARGE syndrome (21) . Embryos injected with Morpholino oligonucleotides (MO) blocking Chd7 protein translation showed defects in the transcriptional circuitry required for neural crest specification and migration. At late tadpole stages Chd7 knockdown led to severe malformations of the craniofacial cartilage, coloboma of the eyes as well as heart defects (21). Similar-although less severe-defects were observed if embryos were injected with an MO blocking the translation of the Sema3a protein (Supplementary Material, Fig. S1 ), supporting previous data suggesting that Sema3a is one of the genes whose expression is regulated by Chd7 (17, 18) . Furthermore, to analyze if Sema3a can rescue the craniofacial malformations of Chd7 morphants, Xenopus embryos were injected in one blastomere at the twocell stage resulting in embryos where the injected side can be directly compared with the uninjected control side (Fig. 1A ). Embryos were injected either with chd7 MO or control MO in combination with lacZ RNA for lineage tracing. For rescue experiments wild-type (wt) human SEMA3A RNA was co-injected. Craniofacial malformations were phenotypically analyzed at tadpole stages (Fig. 1A) . As expected, Chd7 morphants showed severe craniofacial defects on the injected side, while craniofacial structures developed normally on the control side ( Fig. 1B  and C) . These defects could be partially rescued by concomitant overexpression of human SEMA3A. Thus, these data are consistent with a model whereby Chd7 activates Sema3a expression and support a role of SEMA3A as a modifying factor in CHARGE syndrome.
SEMA3A variants are not common disease-modifying factors in CHARGE syndrome CHARGE syndrome patients show a high variability in their clinical presentation, ranging from mild to severe, which may be caused by mutations in additional modifying factors. To elucidate if typically affected CHARGE patients carry, in addition to a pathogenic CHD7 mutation, a SEMA3A variant acting as a modifier, we screened 31 CHD7-positive CHARGE patients grouped into typical or atypical according to the clinical criteria of Blake and/or Verloes (22, 23) . An overview of the clinical details is given in Supplementary Material, Table S1 . The coding region of SEMA3A (NM_006080.2) was sequenced in all 31 patients. In one patient we identified the non-synonymous SEMA3A variant c.2002A>G (p.I668V) in a heterozygous state (Patient 9; Supplementary Material, Table S1 ). This mutation leads to an amino acid substitution from Isoleucin to Valine at position 668 and was recently also described in one out of 45 CHD7-negative CHARGE patients screened for SEMA3A variants (17) . The variant is not listed in the Exome Aggregation Consortium (ExAC) database and its functional relevance is currently unknown. Therefore, we turned again to the Xenopus system to test if this variant is able to rescue the craniofacial defects observed in Chd7 morphant embryos (Fig. 1B and C) . In addition, we tested the SEMA3A variant p.R66W, which was recently identified in a heterozygous state in patients with Kallmann syndrome and suggested to affect SEMA3A secretion. Co-expression of the human SEMA3A variant p.I668V significantly improved the Xenopus Chd7 loss of function phenotype, indicating that this mutant is not pathogenic. In contrast, co-expression of the p.R66W variant did not rescue the craniofacial defects caused by Chd7 knockdown, supporting the notion that this mutation has a pathogenic effect (Fig. 1B and C) .
Next, we analyzed if the SEMA3A mutations affect protein expression or secretion and if this may contribute to their pathogenic or benign effects. Recently, the p.R66W variant was suggested to cause defects in protein secretion. Hanchate et al. showed that conditioned medium from transfected COS-7 cells contains secreted wt SEMA3A protein, but not the p.R66W variant (8) . However, as the intracellular SEMA3A expression was not analyzed, it remains unclear if this result was caused by an expression or secretion defect. Therefore, here we used cell lysates as well as media of transfected HEK293 cells to analyze the processing and secretion of different SEMA3A protein variants. For Class 3 semaphorins monomeric, dimeric, and processed forms have been described (24) . Figure 2A and B shows schematic representations of full-length Sema3a, the predicted processing sites, and the potential isoforms, which may result from proteolytic cleavage as well as dimerization. In order to check for monomeric and dimeric SEMA3A isoforms, concentrated media and cell lysates were analyzed in presence or absence of the reducing agent DTT. In presence of DTT monomeric isoforms of $85/87 kDa (monomer p85 or p87) and $61 kDa (monomer p61) were detected in the concentrated media; without DTT dimeric isoforms of $170/174 kDa (dimer p85:p85 or p87:87) and a weak band of $122 kDa, corresponding to the dimeric form p61:61, were detected as well as monomers of $82 kDa (p82) and $61 kDa. In lysates without DTT a weak band corresponding to the dimeric isoform of $170/174 kDa, as well as the dimeric isoform of $122 kDa (p61:p61) were detected. In cell lysates with DTT only the monomeric isoform of $85/ 87 kDa was observed (Fig. 2B) . We did not detect any alterations in expression or processing pattern for wt SEMA3A or the SEMA3A variants p.R66W and p.I668V (Fig. 2C ). SEMA3A is a glycosylated protein. To determine if the mutations have an influence on the glycosylation status of SEMA3A, we treated the cells with tunicamycin, an inhibitor of N-linked glycosylation. In presence of tunicamycin the variant p.R66W showed two bands, likely corresponding to the glycosylated and unglycosylated forms, while for wt SEMA3A and the p.I668V variant only a single band, corresponding to the unglycosylated form, could be detected. In addition, Western blot analysis of concentrated media from transfected HEK293 cells, producing HA-tagged wt S2 ). These results were confirmed by Western blot analysis using a Sema3a-antibody, which revealed the same monomeric and dimeric endogenous Sema3a isoforms as already observed for overexpressed SEMA3A in HEK293 cell lysates and media ( Fig. 3B ; see also Fig. 2C ). Furthermore, these data were confirmed by transfecting a HA-tagged Sema3a full-length construct and performing Western blot analysis using an anti-HA antibody. In summary, our results demonstrate that Sema3a is expressed, processed, and secreted by O9-1 cells, suggesting that neural crest cells provide a source of Sema3a.
Chd7 binds to the Sema3a promoter and regulates Sema3a expression in murine and Xenopus neural crest cells
Recently, we showed by microarray analysis and quantitative reverse transcription PCR (qRT-PCR) on RNA from Chd7-deficient mouse embryos that a downregulation of Chd7 leads to a downregulation of Sema3a (17) . In order to determine whether this regulatory loop also plays a role in neural crest cells, we analyzed Sema3a expression in explanted Xenopus neural crest cells. Neural crest explants from Xenopus embryos, injected either with 10 ng control MO or chd7 MO, were dissected at premigratory stages and Sema3a expression was analyzed by RT-PCR (Fig. 4A) . RT-PCR showed that sema3a expression can be detected in both control MO and chd7 MO injected neural crest cells. However, compared with control cells, sema3a expression was significantly reduced in chd7 knockdown neural crest cells.
To further confirm these data in murine O9-1 cells, which also express Sema3a and Chd7, O9-1 cells were transfected with two different short interfering RNAs against Chd7. RNA was isolated from O9-1 cells 48 h after siRNA transfection and analyzed by qRT-PCR. Compared with O9-1 cells transfected with a control siRNA, a reduced relative Chd7 expression between 65 and 70% was observed in O9-1 cells transfected with siRNA against Chd7 (Fig. 4B) . Thus, downregulation of Chd7 expression leads to a significant reduction in the Sema3a expression in Xenopus neural crest cells as well as in the murine cranial neural crest cell line O9-1.
Finally, we used chromatin immunoprecipitation (ChIP) for Chd7 to determine if Chd7 interacts with the promoter region of Sema3a. Therefore, ChIP followed by qRT-PCR on chromatin from O9-1 cells was performed. As a positive control we used Sema3c and Nkx2.5-Ar2, while an IgG antibody or no antibody was used as negative controls for the immunoprecipitation. These experiments confirmed an enrichment of Chd7 at the promoter region of Sema3a, Sema3c, and Nkx2.5-Ar2 (Fig. 5) . Thus, these data support an epigenetic link, by which Chd7 activates the expression of Sema3a, and indicates a role of SEMA3A in the pathogenesis of CHARGE syndrome.
Discussion
Neural crest cells are multipotent migratory cells that migrate from the dorsal region of the neural tube to several regions of the developing embryo. Neural crest cells give rise to diverse cell types, such as peripheral neurons, glia, craniofacial chondrocytes, smooth muscle, and pigment cells (27) . Furthermore, neural crest cells contribute to parts of the cardiac outflow tract. Syndromes, which are caused by defects in neural crest development, are commonly referred to as so called 'neurocristopathies'. Some of the defining features of CHARGE syndrome, like craniofacial defects, inner ear malformations, cleft palate and conotruncal heart defects, suggest that it belongs to the neurocristopathies. Consistently, it was shown that CHD7, the gene mutated in CHARGE syndrome patients, is required at specific stages of neural crest development. For example, an essential role of Chd7 was shown in the activation of a transcriptional network, including Sox9, Twist, and Snail2, which is necessary for neural crest migration and specification (21) . Moreover, Chd7 seems to be involved in later steps of neural crest migration and differentiation. By performing a genome-wide microarray expression analysis on wt and Chd7-deficient mouse embryos, we could recently demonstrate that a reduction of Chd7 expression leads to differences in the expression levels of genes involved in neural crest cell migration, guidance, and ectoderm to neural crest cell interactions (17) . One of these genes is Sema3a, a Class 3 semaphorin known to be involved in the pathogenesis of Kallmann syndrome and mutated in an autosomal recessive type of syndromic short stature.
To elucidate the functional role of SEMA3A in the pathogenesis of CHARGE syndrome, we used Xenopus laevis as a model organism. We showed that loss of Sema3a phenocopies aspects of the Chd7 loss of function phenotype in Xenopus neural crest development. Interestingly, these effects are less severe compared with Chd7 loss of function, which may be explained by the fact that sema3a comprises only one of the genes affected by Chd7 loss of function. Furthermore, by performing Chd7 knockdown experiments in Xenopus laevis embryos, we were able to partially rescue the CHARGE phenotype by injection of human SEMA3A wt RNA, confirming the hypothesis of a functional relevance of SEMA3A in the pathomechanism of CHARGE syndrome.
For CHARGE syndrome a high inter-and intra-familial variability of the clinical presentation was observed, suggesting that mutations in additional genes can act as modifiers by enhancing or suppressing the CHD7 phenotype. Thus, we asked if SEMA3A variants are a modifying factor in CHARGE syndrome. To this end we screened for SEMA3A variants in 31 CHARGE patients with a pathogenic CHD7 mutation, grouped into having a typical or atypical phenotype according to the clinical criteria from Blake and/or Verloes (22, 23) . In one patient we identified the non-synonymous variant c.2002A>G (p.I668V) in SEMA3A in a heterozygous state. The functional relevance of this variant is unknown. Therefore, we performed further analysis to elucidate the character of this variation and the c.196C>T (p.R66W) variant, found in a patient with Kallmann syndrome and recently described as pathogenic owing to impaired secretion of the mutated protein (8) . Using transfected HEK293 cells no expression, processing, glycosylation or secretion defects could be observed for the p.I668V variant compared with overexpressed wt SEMA3A, suggesting that this variant is not pathogenic. In contrast, for the p.R66W we observed a secretion defect and abnormalities in the glycosylation pattern, which may indicate that the protein is misfolded and subsequently abnormally glycosylated. For example, N-glycans can serve as a tag for the endoplasmic reticulum (ER) chaperons to control the folding status of a protein. Correctly folded proteins can leave the ER, while misfolded proteins are subject to proteasome-mediated degradation (28). Therefore, it is possible that the secretion defect of the variant p.R66W is simply caused by an increase in degradation compared with wt SEMA3A. Confirming a pathogenic effect of the p.R66W variant, we find that the Xenopus laevis Chd7 loss of function phenotype cannot be rescued by overexpression of the SEMA3A variant p.R66W. In contrast, the variant p.I668V leads to a partial rescue, indicating that the p.I668V variant is benign. Thus, although SEMA3A variants play a role in the pathogenesis of Kallmann syndrome, our results suggest that SEMA3A variants are not common disease modifying factors in CHARGE syndrome. One explanation could be that a reduced CHD7 expression, like in CHARGE syndrome patients, leads to a downregulation of SEMA3A. Therefore, an additional mutation in SEMA3A may not add to the pathogenic effect. Interestingly, autosomal recessive loss of function mutations in SEMA3A were recently described to be causative for a syndromic form of short stature in two unrelated affected boys with postnatal short stature, skeletal abnormalities, hypogonadotropic hypogonadism, micropenis, muscular hypotonia, delayed motor development, cardiovascular anomalies, and mild facial dysmorphism (19, 20) . Although the disorders are distinct, several clinical features of the SEMA3A syndromic short stature phenotype overlap with CHARGE syndrome. For example skeletal abnormalities like scoliosis, kyphosis or abnormalities of the vertebral bodies and costal defects, limb anomalies as well as short stature and hypogonadotropic hypogonadism with micropenis were described in CHARGE syndrome patients (29) (30) (31) .
Sema3a belongs to a subgroup of secreted proteins of the semaphorin family, which bind to plexin or neuropilin receptors in order to mediate repulsive or attractive signals to guide neural crest cells to their destination. For Sema3c, another Subgroup 3 semaphorin, it was recently shown that a subpopulation of cardiac neural crest cells does not respond to guidance factors as expected. Instead, it was demonstrated that these cardiac neural crest cells express Sema3c thereby offering a substantial source of Sema3c (25) . To test if this is also the case for Sema3a, we performed expression analysis for Sema3a in the murine cranial neural crest cell line O9-1. Indeed, we could demonstrate that O9-1 cells express, process, and secrete Sema3a. Furthermore, the described regulatory loop between Chd7 and Sema3a could also be observed in O9-1 cells. A Chd7 knockdown by siRNA leads to a reduction of the Sema3a expression. This could also be confirmed in Chd7 morphant Xenopus laevis neural crest explants.
For Sema3c a direct transcriptional regulation through Chd7 was postulated because Chd7 was shown to localize at the Sema3c promoter (18) . To investigate if this is also the case for Sema3a, we performed a ChIP for Chd7, followed by qRT-PCR on chromatin from O9-1 cells, and could observe an enrichment of Chd7 at the promoter region of Sema3a, identifying Sema3a as a direct target of Chd7.
Although it seems that SEMA3A variants are not common modifying factors in CHARGE syndrome, our results suggest that Sema3a is part of a regulatory network that is compromised in CHARGE syndrome. As Sema3a expression is regulated by Chd7, pathogenic mutations in CHD7 also affect SEMA3A expression and function. Thereby, SEMA3A likely plays an important role in the pathogenesis of CHARGE syndrome by acting as a downstream CHD7 target.
Materials and Methods
Cell culture, treatment and transient transfection Roth) . Before treatment, the transfection media was exchanged for tunicamycin or DMSO medium, respectively. Sixteen hours later, cells were harvested for further analysis. All experiments were performed three times.
SEMA3A constructs and site-directed mutagenesis
The entire open reading frame of human wt SEMA3A as well as murine wt Sema3a was amplified by PCR and cloned into the pCMV-HA vector using the In-Fusion V R HD Cloning Kit (Clontech) according to the manufacturer's protocol. For the Xenopus laevis experiments SEMA3A was cloned from the pCMV-HA vector into the pcDNA3.1/myc-His B vector using the In-Fusion V R HD Cloning Kit (Clontech). To introduce the point mutations c.196C>T (p.R66W) and c.2002A>G (p.I668V), a site directed mutagenesis PCR, using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies), was performed according to the manufacturer's protocol. Primer sequences can be sent on request.
Because semaphorin-3A is synthesized as an inactive precursor and undergoes proteolytic cleavage, we introduced a HAtag (YPYDVPDYA) after the signal peptide of Sema3a (G25-K26) (24) by PCR site-directed mutagenesis. Plasmids were sequenced to validate the correct sequence. Primer sequences can be sent on request.
Western blot analysis
To concentrate the media of O9-1 and HEK293 cells, Vivaspin Turbo 15 columns (30 kDa MWCO, Sartorius) were used. Thirty micrograms of protein or 18 ml concentrated medium were separated by a 4-12% NuPAGE Bis-Tris Gel (Invitrogen) and transferred to a nitrocellulose membrane (0.45 mm) (GE Healthcare) using a Tank system at 250 mA for 60 min at 4 C. Membranes were blocked with 5% milk/TBST (Carl Roth) for 60 min and afterwards incubated with appropriate primary antibodies overnight at 4 C. Rat anti-HA (11867431001, Sigma Aldrich) was used at a dilution of 1:1000 in 2% milk/TBST. Rabbit anti-Sema3a (ab23393, Abcam) was diluted 1:1000 in 2% milk/TBST. After washing, the membrane was incubated with the following secondary antibodies: anti-rat IgG peroxidase secondary antibody (31470, Pierce) at a dilution of 1:10 000 in 2% milk/TBST, goat IgG anti-rabbit (H þ L)-HPRO (A8275, Sigma) at a dilution of 1:10 000 in 2% milk/TBST. The membrane was washed three times with TBST, Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore) was applied to the membrane, and positive bands were detected using FluorChem V R Q (Alpha Innotech). Protein quality was controlled using mouse anti-a-tubulin (T5168, Sigma Aldrich) at a dilution of 1:10 000 in 2% milk/TBST. The experiments were performed three times.
Chromatin immunoprecipitation (ChIP)
ChIP analysis of O9-1 cells was performed at least three times as described before (32) , 6 ml 5 M NaCl and 2 ml Proteinase K (10 mg/ml)] for 2 h at 62 C and 10 min at 95 C. DNA fragments were purified using spin columns (Invitek). The enrichment was analyzed by real-time PCR using locus-specific primers. Data were normalized to 2% input and compared with the enrichment at non-specific loci.
Micromanipulation of Xenopus laevis embryos
Xenopus laevis embryos were obtained by in vitro fertilization and injected and cultivated as previously described (34) . Stages were determined according to Nieuwkoop and Faber (35) . Synthesis of capped sense RNA for injection was performed in vitro using the mMessage mMachine kit TM (Ambion, Thermo Fisher Scientific).
Digoxigenin-labeled antisense RNA for in situ probes was generated with a DIG-RNA labeling kit (Roche). The following linearized plasmids were used for RNA synthesis: lacZ (36), GFP (37), Sema3a MT (6Â myc-tag) (38) and Twist (39). SEMA3A constructs were synthesized and cloned into the pcDNA3. Embryos were injected in one blastomere at the two-cell stage for in situ hybridization and analysis of craniofacial structures. b-galactosidase (lacZ) mRNA, coding for the enzyme bacterial b-galactosidase, was co-injected as a lineage tracer. After fixation in MEMFA (3.7% formaldehyde, 0.1 M MOPS, 2 mM EGTA, 1 mM MgSO 4 ), X-gal staining was performed as described (34, 40) . Whole mount in situ hybridization was performed according to previous protocols (40) , using a Digoxigenin labeled Twist antisense RNA probe to mark neural crest cells. Embryos for RT-PCR were injected in both blastomeres at the two-cell stage, and neural crest explants were dissected at premigratory neural crest cell stages. For the Chd7 loss-of-function rescue experiments, different combinations of chd7 MO or control MO (5 ng) and SEMA3A or GFP mRNA constructs (250 pg) were injected as indicated in the figure legends. GFP overexpression served as a negative control. Embryos were cultivated until stage 38-42 and phenotypically analyzed for craniofacial defects.
RT-PCR of Xenopus neural crest explants
For RT-PCR embryos were co-injected with 10 ng control MO or chd7 MO and 50 pg GFP RNA as a lineage tracer. A total of 100 cranial neural crest explants per condition were dissected from both sides of injected embryos at stages 17-18 as described (41) and immediately frozen in liquid nitrogen. RNA isolation was performed using the Illustra RNAspin Mini Kit (GE Healthcare). MuLV Reverse Transcriptase (Thermo Fisher Scientific) was used for cDNA synthesis. RT-PCR for histone H4 and sema3a was conducted with the following primer-pairs: H4_fw CGGGATA ACATTCAGGGTATCACT, H4_rv ATCCATGGCGGTAACTGTCTTC CT, Sema3a_fw TACATTGGCTCGTCAGTGGG, Sema3a_rv AAA ACTAGGGCACGCTGTGA. PCR was performed with 32-35 cycles using the DreamTaq DNA Polymerase (Thermo Fisher Scientific). Quantitative analysis of PCR-bands was carried out via the Image Studio software of Odyssey V R Fc Imaging System (LI-COR Bioscience). The ratio between Sema3a and histone H4 expression was calculated to normalize for initial variations in sample concentration.
Patients
Thirty-one patients were included in the study, from which 17 were recruited from the University Medical Center Groningen (UMCG). Patients with a confirmed CHD7 mutation were selected from whom DNA was available. The patients were grouped in typical or atypical CHARGE patients according to the clinical criteria of Blake (22) and/or Verloes (23) . The collaboration to this study has been exempted from ethical review by the Medical Ethical Review Committee of the UMCG and UMG.
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Supplementary Material is available at HMG online.
